Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies.

ABSTRACT:

Background

The recruitment of underrepresented racial and ethnic groups in clinical trials remains a challenge.

Methods

The ClinicalTrials.gov database was queried for phase III trials related to non-Hodgkin lymphoma (NHL), leukemia, and multiple myeloma (MM). A reference population was sourced from the Surveillance, Epidemiology, and End Results (SEER) database.

Results

A total of 53,821 pooled participants from 119 phase III trials were included in the analyses. Race and ethnicity data were reported in 95.8% and 81.5% of trials, respectively. Globally, the majority of participants were predominantly White (77.3%), followed by Asian (8.2%), Black/African American (5.4%), American Indian/Alaska Native (0.4%), and Native Hawaiian/Other Pacific Islander (0.2%), while Hi

SUBMITTER: Wang T 

PROVIDER: S-EPMC12456206 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature